COPART, INC. vs WILLIAMS-SONOMA, INC., two Retail stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Copart's salvage-auction platform keeps 33.48% of revenue, the fattest margin in this group, and it does so with no debt and a $28.8B market value. Williams-Sonoma sells home furnishings, a $28.7B retailer keeping 13.81% net, strong for its aisle though less than half Copart's rate. Williams-Sonoma also carries no net debt and returns 3.81% in free cash plus a 1.1% dividend. Copart returns 4.65% in free cash and pays nothing out. On earnings Copart is the cheaper of the two, 19.06 times against 26.82. A fee business on wrecked cars beside a brand business on kitchens and couches, both clean of leverage.
Comparison updated 2026-07-11.
| Metric | CPRT | WSM |
|---|---|---|
| Price | $27.52 | $221.72 |
| Market cap | $25.9B | $26.6B |
| Sector | Retail | Retail |
| Stage | Mature | Mature |
| Implied growth (priced in) | +5.4% | +33.2% |
| P/E | 17.2 | 24.9 |
| P/B | 2.96 | 14.22 |
| P/S | 5.59 | 3.37 |
| EV/EBITDA | 13.9 | 17.6 |
| Revenue growth | +1.1% | +1.8% |
| Gross margin | — | 44.0% |
| Operating margin | 37.5% | 16.2% |
| Net margin | 33.5% | 13.8% |
| Return on equity | 17.7% | 58.2% |
| Return on assets | 16.1% | 21.5% |
| Return on invested capital | 15.4% | 58.7% |
| FCF yield | 5.2% | 4.1% |
| Dividend yield | — | 1.2% |
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.61 | 1.33 |
| Altman Z (solvency) | 8.31 | 7.26 |
| Piotroski F (quality) | 8 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.